<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439982</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00060782</org_study_id>
    <nct_id>NCT03439982</nct_id>
  </id_info>
  <brief_title>Fecal Transplant for Hepatic Encephalopathy</brief_title>
  <official_title>A Prospective Single Center Open Label Trial of RBX2660 (Microbiota Suspension) in the Management of Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rebiotix Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse&#xD;
      hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes&#xD;
      of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects receive FMT from a single donor by colonoscopy at week 0 and by enema at weeks 1-4.&#xD;
      HE is measured by Inhibitory Control Test (ICT) and Stroop test as well as fasting serum&#xD;
      ammonia levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2016</start_date>
  <completion_date type="Actual">March 18, 2021</completion_date>
  <primary_completion_date type="Actual">August 7, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portion of participants with normalization of ICT or Stroop Test during the study</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normalization ICT or Stroop test scores at 1 week, 2 weeks, 4 weeks and 8</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum ammonia level pre and post FMT</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life measured by Chronic Liver Disease Questionnaire (CDLQ) pre and post FMT</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intestinal Microbiota pre-and post FMT</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>i) All serious adverse events up to and including week 8. A serious adverse event is any event which results in any of the following: i) Death ii) Colonic perforation iii) Proven infections as defined by the presence of i) spontaneous bacteremia: positive blood cultures in the absence of any other potential source of infection; ii) spontaneous bacterial peritonitis: ascetic fluid PMN equal to or greater than 250/mm3; iii) UTI: urinary leukocyte count greater than 15 cells per HPF and positive urine culture; vi) other infections identified by clinical, radiologic and bacteriologic results.&#xD;
iv) Possible infections as defined by i) fever (temp &gt; 37.80 C), ii) leukocytosis (&gt;15,000 mm3) or increased immature neutrophils in blood (&gt;500 mm3), negative cultures and no other signs of infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stool Bile Acids Composition pre and post FMT</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in stool short chain free fatty acids pre and post FMT</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>FMT processed from routinely screened donors</description>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult cirrhotic patients of various etiology on lactulose and/pr rifaximin or&#xD;
             metronidazole for minimum 4 weeks as secondary prophylaxis&#xD;
&#xD;
          -  Abnormal ICT (&gt;5 lures) or abnormal Stroop test (&gt;200 seconds)&#xD;
&#xD;
          -  Baseline Conn score 0 or 1&#xD;
&#xD;
          -  Infectious etiology of HE has been ruled out&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those with tense ascites&#xD;
&#xD;
          -  those who do not provide assent&#xD;
&#xD;
          -  life expectancy &lt;3 months&#xD;
&#xD;
          -  TIPS within the past 3 months&#xD;
&#xD;
          -  neurologic disease such as dementia, Parkinson's, structural brain lesions&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  intestinal obstruction&#xD;
&#xD;
          -  alcoholic hepatitis&#xD;
&#xD;
          -  active alcohol or substance abuse&#xD;
&#xD;
          -  those without stable social support&#xD;
&#xD;
          -  concurrent infection such as spontaneous bacterial peritonitis, pneumonia or urinary&#xD;
             tract infection&#xD;
&#xD;
          -  creatinine clearance less that 50% compared to baseline&#xD;
&#xD;
          -  hospital admission for HE within one month of enrollment&#xD;
&#xD;
          -  active hepatocellular carcinoma&#xD;
&#xD;
          -  active GI bleed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic encephalopathy, fecal microbiota transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

